Practice
Featured experience
Bristol Myers Squibb $13 billion notes offering
The investment-grade offering comprised nine tranches
Cisco Systems $13.5 billion notes offering
The investment-grade offering comprises seven tranches of notes
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Novartis $3.7 billion notes offering
We advised Novartis on the investment-grade debt offering
Eli Lilly $5 billion notes offering
The investment-grade notes are due 2027, 2029, 2034, 2054 and 2064
Life Time $300 million follow-on offering
The shares are listed on the New York Stock Exchange
ANI Pharmaceuticals $316.25 million convertible notes offering
We advised ANI Pharmaceuticals on the offering
Penumbra $100 million accelerated share repurchase
We advised Penumbra on the ASR transaction
Alkami Technology $155.9 million secondary offering
The shares are listed on the Nasdaq Global Select Market
Fiserv $1.75 billion notes offering
The investment-grade debt consists of two tranches of notes
Enova International $500 million notes offering and concurrent tender offer
The high-yield notes are due 2029
Walgreens Boots Alliance $750 million notes offering
We advised Walgreens Boots Alliance on its debt offering
CytomX Therapeutics $58.3 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Precigen $34 million follow-on offering
We advised Precigen on the SEC-registered offering